Ophthalmology Clinical Trials

Current Clinical Trials

Diabetic Macular Edema

  • KalVista Study—A Randomized, Sham-Controlled, Double-masked Phase 2a study of the efficacy, safety and tolerability of the intravitreal plasma kallikrein inhibitor, KVD001, in subjects with center-involving diabetic macular edema (ciDME) who have had prior anti-vascular endothelial growth factor (VEGF) treatment

Sponsor: KalVista Pharmaceuticals, Ltd; Principal Investigator: Yevgeniy Shildkrot, MD

Geographic Atrophy

  • TOGA– Phase II/III, Randomized, Double-Masked, Placebo Controlled Study Evaluating ORACEA in Subjects with Geographic Atrophy Secondary to Non-Exudative Age-Related Macular Degeneration.

Sponsor: UVA Dept. of Ophthalmology; Principal Investigator: Paul Yates, MD, PhD

Leber’s Hereditary Optic Neuropathy (LHON)

  • Leber’s Study— External Natural History Controlled, Open-Label Intervention Study to Assess the Efficacy and Safety of Long-Term Treatment with Idebenone (Raxone®) in Leber’s Hereditary Optic Neuropathy (LHON)

Sponsor: Santhera Pharmaceuticals; Principal Investigator: Steven Newman, MD

Non-Arteritic Anterior Ischemic Optic Neuropathy

  • QRK Study – A Phase 2/3, Randomized, Double-Masked, Sham-Controlled Trial of QPI-1007 Delivered by Single or Multi-Dose Intravitreal Injection(s) to Subjects with Acute Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)

Sponsor: Quark Pharmaceuticals; Principal Investigator: Steven Newman, MD


For additional information about the trials or to refer a patient, contact the study coordinators:

  • Ashton Leone, MPH at (434) 243-5737 or aml7q@virginia.edu
  • Allison Weiderhold at (434) 243-2921 or alw5rm@virginia.edu